These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 28599900

  • 1. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study.
    Halle MK, Ojesina AI, Engerud H, Woie K, Tangen IL, Holst F, Høivik E, Kusonmano K, Haldorsen IS, Vintermyr OK, Trovik J, Bertelsen BI, Salvesen HB, Krakstad C.
    Am J Obstet Gynecol; 2017 Oct; 217(4):432.e1-432.e17. PubMed ID: 28599900
    [Abstract] [Full Text] [Related]

  • 2. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.
    Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van de Vijver MJ.
    Clin Cancer Res; 1999 Mar; 5(3):577-86. PubMed ID: 10100709
    [Abstract] [Full Text] [Related]

  • 3. Tumor hypoxia, p53, and prognosis in cervical cancers.
    Haensgen G, Krause U, Becker A, Stadler P, Lautenschlaeger C, Wohlrab W, Rath FW, Molls M, Dunst J.
    Int J Radiat Oncol Biol Phys; 2001 Jul 15; 50(4):865-72. PubMed ID: 11429213
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May 15; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical assay of p53, cyclin D1, c-erbB2, EGFr and Ki-67 proteins in HPV-positive and HPV-negative cervical cancers.
    Kedzia W, Schmidt M, Frankowski A, Spaczyński M.
    Folia Histochem Cytobiol; 2002 May 15; 40(1):37-41. PubMed ID: 11885807
    [Abstract] [Full Text] [Related]

  • 6. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN.
    Brewer CA, Liao SY, Wilczynski SP, Pastorekova S, Pastorek J, Zavada J, Kurosaki T, Manetta A, Berman ML, DiSaia PJ, Stanbridge EJ.
    Gynecol Oncol; 1996 Dec 15; 63(3):337-44. PubMed ID: 8946869
    [Abstract] [Full Text] [Related]

  • 7. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
    Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS.
    Breast Cancer Res; 2007 Dec 15; 9(3):R30. PubMed ID: 17504517
    [Abstract] [Full Text] [Related]

  • 8. The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients.
    Heidegger H, Dietlmeier S, Ye Y, Kuhn C, Vattai A, Aberl C, Jeschke U, Mahner S, Kost B.
    Int J Mol Sci; 2017 Jul 19; 18(7):. PubMed ID: 28753926
    [Abstract] [Full Text] [Related]

  • 9. The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer.
    Eijsink JJ, Noordhuis MG, ten Hoor KA, Kok M, Hollema H, de Bock GH, Nijman HW, Schuuring E, Wisman GB, van der Zee AG.
    Hum Pathol; 2010 Dec 19; 41(12):1735-41. PubMed ID: 21078436
    [Abstract] [Full Text] [Related]

  • 10. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E, Wild PJ, Wülfing C, Zwarthoff EC, Burger M, Stoehr R, Korsching E, Hartmann A.
    Eur Urol; 2009 Nov 19; 56(5):837-45. PubMed ID: 18945538
    [Abstract] [Full Text] [Related]

  • 11. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, Soares FA.
    J Clin Oncol; 2011 Aug 01; 29(22):3030-6. PubMed ID: 21709195
    [Abstract] [Full Text] [Related]

  • 12. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer.
    Hazelbag S, Kenter GG, Gorter A, Fleuren GJ.
    Int J Cancer; 2004 Dec 20; 112(6):1020-8. PubMed ID: 15386352
    [Abstract] [Full Text] [Related]

  • 13. EGFR (HER) family protein expression and cytogenetics in 219 squamous cell carcinomas of the upper respiratory tract: ERBB2 overexpression independent prediction of poor prognosis.
    Brunner K, Fischer CA, Driemel O, Hartmann A, Brockhoff G, Schwarz S.
    Anal Quant Cytol Histol; 2010 Apr 20; 32(2):78-89. PubMed ID: 20701076
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer.
    Schrevel M, Gorter A, Kolkman-Uljee SM, Trimbos JB, Fleuren GJ, Jordanova ES.
    Mod Pathol; 2011 May 20; 24(5):720-8. PubMed ID: 21252859
    [Abstract] [Full Text] [Related]

  • 15. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.
    Schirosi L, Lantuejoul S, Cavazza A, Murer B, Yves Brichon P, Migaldi M, Sartori G, Sgambato A, Rossi G.
    Am J Surg Pathol; 2008 Nov 20; 32(11):1627-42. PubMed ID: 18753943
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.
    Kristensen GB, Holm R, Abeler VM, Tropé CG.
    Cancer; 1996 Aug 01; 78(3):433-40. PubMed ID: 8697388
    [Abstract] [Full Text] [Related]

  • 17. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.
    Reinartz JJ, George E, Lindgren BR, Niehans GA.
    Hum Pathol; 1994 Oct 01; 25(10):1075-83. PubMed ID: 7927313
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
    Karamurzin Y, Leitao MM, Soslow RA.
    Am J Surg Pathol; 2013 Mar 01; 37(3):356-67. PubMed ID: 23282975
    [Abstract] [Full Text] [Related]

  • 19. Decreased expression of EIF4A1 after preoperative brachytherapy predicts better tumor-specific survival in cervical cancer.
    Liang S, Zhou Y, Chen Y, Ke G, Wen H, Wu X.
    Int J Gynecol Cancer; 2014 Jun 01; 24(5):908-15. PubMed ID: 24844222
    [Abstract] [Full Text] [Related]

  • 20. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A.
    Gynecol Oncol; 2013 Sep 01; 130(3):463-9. PubMed ID: 23777659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.